A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Phase 1/2 Completed
117 enrolled
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Phase 1/2 Completed
29 enrolled
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
215 enrolled 30 charts
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Phase 1/2 Completed
18 enrolled
ICONIC
Phase 1/2 Completed
22 enrolled
INeOV
Phase 1/2 Completed
69 enrolled
Study of ESG401 in Adults With Solid Tumors
Phase 1/2 Completed
156 enrolled
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
87 enrolled 22 charts
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Phase 1/2 Completed
307 enrolled 27 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
KANDOVA
Phase 1/2 Completed
18 enrolled
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Phase 1/2 Completed
62 enrolled 29 charts
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Phase 1/2 Completed
247 enrolled 15 charts
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Completed
12 enrolled
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Phase 1/2 Completed
79 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Phase 1/2 Completed
152 enrolled
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Phase 1/2 Completed
26 enrolled 14 charts
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Phase 1/2 Completed
28 enrolled 9 charts
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
Phase 1/2 Completed
5 enrolled 8 charts
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Phase 1/2 Completed
48 enrolled
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Phase 1/2 Completed
22 enrolled 10 charts
4FMFES-PET Imaging of Endometrial and Ovarian Cancers
Phase 1/2 Completed
53 enrolled
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase 1/2 Completed
78 enrolled 15 charts
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
Phase 1/2 Completed
35 enrolled
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Phase 1/2 Completed
140 enrolled 25 charts
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Phase 1/2 Completed
88 enrolled
MYCA
Phase 1/2 Completed
87 enrolled
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Phase 1/2 Completed
49 enrolled
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Phase 1/2 Completed
113 enrolled 22 charts
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Phase 1/2 Completed
41 enrolled
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Phase 1/2 Completed
136 enrolled 30 charts
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Phase 1/2 Completed
7 enrolled 10 charts
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase 1/2 Completed
40 enrolled 15 charts
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Phase 1/2 Completed
46 enrolled
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Phase 1/2 Completed
67 enrolled 16 charts
TOPACIO
Phase 1/2 Completed
122 enrolled 29 charts
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Phase 1/2 Completed
53 enrolled 22 charts
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Completed
29 enrolled 17 charts
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
Phase 1/2 Completed
155 enrolled
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Phase 1/2 Completed
444 enrolled 19 charts
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Phase 1/2 Completed
195 enrolled 51 charts
AdORN
Phase 1/2 Completed
18 enrolled 15 charts
ACT
Phase 1/2 Completed
150 enrolled
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Phase 1/2 Completed
33 enrolled 70 charts
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
Phase 1/2 Completed
60 enrolled 11 charts
Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
Phase 1/2 Completed
51 enrolled